Among 32 pharma and biotech companies surveyed, structure-based drug design is the most prevalent activity with the most players emphasizing the fragment-based variation.

FACT:

WHAT’S NEW THIS YEAR:

May 21 - 22, 2014 | Westin Boston Waterfront | Boston, MA

Structure-Based Drug DesignUsing Structure and Rational Design to Accelerate Discovery

Fourteenth Annual

FACTS & FIGURESDrug Discovery

PRSRT STD US POSTAGE PAID PERMIT NO. 6HUDSON, MA

CAMBRIDGE HEALTHTECH INSTITUTE250 First Avenue | Suite 300Needham, MA 02494

Hear case studies from:• Arena Pharmaceuticals

• Astex

• AstraZeneca

• Bristol-Myers Squibb

• Carmolex

• Carmot Therapeutics

• Constellation Pharmaceuticals

• Genentech

• Heptares Therapeutics UK

• Merck

• Novartis

• Structural Genomics Consortium

• Takeda

• Vernalis, Ltd.

• Coverage of novel targets and compounds including macrocycles, epigenetic targets, and BACE inhibitors

• Case studies and experimental follow up - see how Constellation, Heptares, AstraZeneca, and others are leading the SBDD charge

• Expanded sessions on GPCR design and drug discovery

• Showcase of different approaches for working with the similar targets

Structure-Based Drug DesignUsing Structure and Rational Design to Accelerate Discovery

Fourteenth Annual

CONSIDER THISThe average cost of bringing a new drug to market is $1.3 billion

FACT:Fewer than 1 in 10 medicines that start being tested in human clinical trials will succeedIn 2012 the FDA approved

39 new drugs

FACT:

FACT:

Enzymes 47%Other Receptors 4%Integrins 1%

DNA 1%Miscellaneous 2%

GPCRs 30%

Ion Channels 7%

Nuclear Hormone Receptors and

Transporters 8%

Current Drug Target Breakdown

The pharmaceutical market will reach nearly

USD by 2016

FACT:$1,200,000,000,000

Structure-Based Drug Designconference help to advance the drug discovery field?

How will CHI’s 14th Annual

By addressing topics that matter:

Executive

Director

Manager

Professor

Scientist/Technologist

Sales & Marketing

Other

11%

12%

8%

12%

46%

6%

5%

USA

Europe

Asia

ROW

60%

25%

10%

5%

Computational Chemistry

Medicinal Chemistry

Drug Discovery

Discovery Technologies

Structural Biology

Structural Chemistry

Biochemistry

Molecular Modeling

Other

15%

17%

13%

6%

9%

13%

11%

5%

11%

Academic

Biotech

Government/ Research Institutions

Pharmaceutical

24%

41%

3%

32%

Attendee Profile

By bringing together industry leaders:

Title

Region

Function

Company Type

Keynote Speaker Chas Bountra, Ph.D., Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford

Sources: Forbes, Insight Pharma Reports: Medicinal Chemistry, FDA.gov

Register and View Full Details:healthtech.com/structure-based-drug-design

Register by February 28 and Save up to $400!Mention keycode “INW” when registering

GPCRs

New techniques and strategies

Novel targets and compounds

25%

50%

45%